Cyclacel Pharmaceuticals, Inc.'s Novel Polo-Like Kinase 1 (Plk1) Inhibitors Highlighted at American Association for Cancer Research

BERKELEY HEIGHTS, N.J., April 2, 2012 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, announced today the presentation of translational research findings and characterization of selective Polo-Like Kinase 1 (Plk1) and Aurora A kinase inhibitors discovered by Cyclacel during the 103rd Annual Meeting of the American Association of Cancer Research (AACR) 2012 in Chicago, IL.